Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Real-world Study of Consolidation Durvalumab for Stage III Unresectable Non-small Cell Lung Cancer in China and Safety Data on Durvalumab in Chinese Patients With Lung Cancer（PACIFIC-PUMCH-R）

NCT04672759 is registered in ClinicalTrials.gov with Peking Union Medical College Hospital as lead sponsor.

NCT NCT04672759
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04672759 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Real-world Study of Consolidation Durvalumab for Stage III Unresectable Non-small Cell Lung Cancer in China and Safety Data on Durvalumab in Chinese Patients With Lung Cancer（PACIFIC-PUMCH-R）
Lead sponsor
Peking Union Medical College Hospital
Phase
Observational
Overall status
Unknown status
Start date
July 28, 2020
Completion date
October 31, 2024
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer stage iii, small-cell lung cancer